Twinbeech Capital LP Amylyx Pharmaceuticals, Inc. Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $359,996 - $2.6 Million	-132,840 Reduced 79.81%	33,604 $95,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $1.02 Million - $1.57 Million	84,860 Added 104.02%	166,444 $2.45 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $1.35 Million - $1.75 Million	-74,464 Reduced 47.72%	81,584 $1.49 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $509,310 - $762,751	24,276 Added 18.42%	156,048 $3.37 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $3.65 Million - $5.39 Million	131,772 New	131,772 $3.87 Million

142

49.1M

281K

438K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $214M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.